Form 4: Ionis Pharmaceuticals Executive Richard S. Geary Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
EVP and Chief Development Officer of Ionis Pharmaceuticals, Richard S. Geary, executed sales of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Richard S. Geary, EVP and Chief Development Officer at Ionis Pharmaceuticals, sold shares of common stock on August 28 and 29, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on April 8, 2024.
- On August 28, 2024, 320 shares were sold at a price of $49.16 per share.
- On August 29, 2024, 331 shares were sold at a price of $49.63 per share.
- Following these transactions, Geary directly owns 84,823 shares of Ionis Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document simply reports stock sales under a pre-arranged plan, indicating a neutral sentiment.
Industry Context
Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of acting on inside information.
Stakeholder Impact
- The stock sales may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 04/08/2024 | Date the reporting person adopted the Rule 10b5-1 Trading Plan |
| 08/28/2024 | Date of first stock sale: 320 shares at $49.16 |
| 08/29/2024 | Date of second stock sale: 331 shares at $49.63 |
| 09/03/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.